Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Low-dose lipopolysaccharide pretreatment enhanced the proliferation and antibacterial activity of human adipose-derived mesenchymal stem cells.

Li L., Diao J., Wang F., Wang X., Liu Y., Fu X.

Animal Study on Immune Modulation, published in Regen Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Regen Ther (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
41541822
PMCID
PMC12800635
DOI
10.1016/j.reth.2025.101057

Abstract (original English)

Introduction Adipose-derived mesenchymal stem cells (ADSCs) have been widely investigated for their pro-angiogenic and immunomodulatory roles in the repair of infected wounds. However, the direct antimicrobial effects of ADSCs and the underlying regulatory mechanisms remain poorly characterized. In particular, the functional modulation of ADSCs by low-dose lipopolysaccharide (LPS) preconditioning has not been systematically investigated. Methods We evaluated the effects of LPS preconditioning on the proliferation and apoptosis of human ADSCs (hADSCs), as well as the antimicrobial activity and wound-healing potential of hADSC-conditioned medium (hADSC-CM). Results Analysis demonstrated that at concentrations ranging from 10 to 500 ng/mL, LPS significantly enhanced the proliferation of hADSCs, with the highest viability observed at 500 ng/mL and no evidence of increased apoptosis. Moreover, LPS preconditioning markedly upregulated the expression of antimicrobial peptides (LL-37 and HBD-2) in hADSC-CM, leading to improved inhibition of Staphylococcus aureus and Escherichia coli growth. In vivo experiments further confirmed that 500 ng/mL of LPS-hADSC-CM significantly accelerated the healing of infected wounds, increased collagen deposition, and downregulated the expression of iNOS, thus suggesting enhanced inflammation resolution and tissue regeneration. Conclusion These findings

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research